Motrin's "strong performance" helps J&J second quarter but consumer sales still down.
This article was originally published in The Tan Sheet
Executive Summary
McNEIL MOTRIN "STRONG PERFORMANCE" HELPS J&J CONSUMER SALES in the second quarter; however, the segment as a whole showed a sales decline for both the quarter and the half. Consumer product sales were helped by "strong performances from the adult and children's Motrin line of analgesics," as well as lead by "continued strength" in the company's skin care franchise, including the Neutrogena, RoC and Clean & Clear lines, Johnson & Johnson announced July 14.